Risk of Uveitis with Spondyloarthritis

Save

A retrospective registry study shows that uveitis may be seen in 10% with the diagnosis of axial spondyloarthritis (axSpA) but becomes more common (47%) over the next 30 years of disease. The good news is that biologic therapy can significantly lower the risk of uveitis in (SpA).

Long Term Antibiotics Increase Risk of RA

Save

JAMA has published a population-based retrospective cohort study showing a possible association between the long-term use of antibiotics and the risk of rheumatoid arthritis (RA).

2023 EULAR Recommendations on Management of Fatigue

Save

Declining Menopausal Hormone Therapy in Postmenopausal Women

Save

A two decade cross-sectional population study has shown a marked downward trend in menopausal hormone therapy (MHT), with an over 80% reduction, especially in women aged 52 - 65 years.

Which One is the Loneliest Number (9.27.2024)

Save

Dr. Jack Cush reviews the regulatory approvals, announcements, guidelines and interesting journal articles from the past week on RheumNow.com. When not to use muscle relaxants, how frequent is loneliness in RA/PsA/SpA, and when to refer patients with Still's disease.

Stratified Cancer Screening in Dermatomyositis

Save

The International Myositis Assessment and Clinical Studies Group (IMACS) have published  evidence and consensus based cancer screening guidelines for patients with idiopathic inflammatory myopathies, including dermatomyositis. 

EULAR/PReS Still's Disease Management Recommendations

Save

Since 2022, EULAR and the Paediatric Rheumatology European Society (PReS) have been working to establish clinical practice guidelines for the diagnostics and management of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD). 

Pain Relief with JAK Inhibitors or Anti-TNFs ?

Save

Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.

INVIGORATE-2 Study - IV Secukinumab in Active Psoriatic Arthritis

Save

The INVIGORATE-2 trial reports that intravenous secukinumab is both effective and safe in patients with active psoriatic arthritis, demonstrating improvements on par with subcutaneous secukinumab.